par
Gus Iversen, Editor in Chief | March 23, 2026
TerraPower Isotopes (TPI), a subsidiary of the Bellevue, Washington-based nuclear technology company TerraPower, said it will build a current Good Manufacturing Practices (cGMP) facility in Philadelphia to produce actinium-225, a radioisotope used in targeted cancer therapies.
The site, located in the Bellwether District, is expected to begin production in 2029 following a multiyear construction process. The company said the new facility, combined with planned expansions at its existing site in Everett, Washington, will increase its actinium-225 production capacity by a factor of 20.
Actinium-225 is being studied in clinical trials as part of targeted alpha therapies, an emerging class of radiopharmaceutical treatments. Supply constraints have been a limiting factor for broader research and development efforts, particularly as more drugmakers explore the isotope’s use across oncology indications.
Ad Statistics
Times Displayed: 17108
Times Visited: 38 Stay up to date with the latest training to fix, troubleshoot, and maintain your critical care devices. GE HealthCare offers multiple training formats to empower teams and expand knowledge, saving you time and money.
“TerraPower’s mission is to deliver new technologies to market that can improve lives; and the work our TerraPower Isotopes team is doing shows real promise in supporting the expansion of a diverse suite of cancer treatments using nuclear medicine,” said Chris Levesque, president and CEO of TerraPower. “This new facility will help us increase the global supply of actinium-225 and increase access for researchers and drug developers who are advancing new cancer treatments.”
The company said it evaluated more than 350 potential locations across the U.S. before selecting Philadelphia, citing proximity to research institutions and existing life sciences infrastructure. Regional stakeholders said the project reflects continued growth in radiopharmaceutical development in the area.
“TPI’s Actinium-225 is already enabling clinical programs around the world as a key component of next-generation targeted alpha therapies,” said Jaap Duiker, managing director at Von Gahlen. “This new facility represents a critical step in expanding and strengthening the infrastructure required to accelerate the transformation of cancer treatments.”
TPI is part of TerraPower, which was founded by Bill Gates and focuses on nuclear energy and related technologies, including medical isotope production.
